February 4, 2022 12:57 PM EST
R&D

Pfiz­er lands on For­tune’s most ad­mired list, edg­ing out Dis­ney, Google and Star­bucks in an­nu­al rep­u­ta­tion rank­ing

Beth Snyder Bulik

Senior Editor

The Covid-19 vac­cine ha­lo con­tin­ues for Pfiz­er. This week, the Big Phar­ma came in at No. 4 on For­tune’s an­nu­al rank­ing of the most ad­mired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times